All News

The pause request comes as the administration considers whether to keep current federal rules in place that allow for remote access to mifepristone.

A central focus is understanding and reducing patient-level barriers to timely, values-congruent fibroid care

A new AHA scientific statement outlines how earlier prevention, rapid diagnosis and timely treatment can reduce the risks of maternal stroke during pregnancy and postpartum.

New national data show major declines in RA mortality among older women, alongside enduring racial and geographic inequities.

Menopause was associated with increased anxiety, depression, sleep problems and reductions in grey matter in key brain regions.

New FDA guidance and AACR-bound data highlight Aviva Bio’s progress in developing a differentiated testosterone therapy aimed at reducing breast cancer risk in women.

The AAP'S 2026 schedule has been endorsed by 12 medical and health organizations, including the American College of Nurse Midwives and the American College of Obstetricians and Gynecologists.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Longer lifetime breastfeeding was associated with lower odds of depression and anxiety up to 10 years later in a prospective cohort of midlife women.

A large cohort study found that prenatal exposure to acid-suppressive medications was not associated with neuropsychiatric disorders in children.

Self-collected hrHPV testing, now supported in HRSA’s cervical cancer screening guidelines, could dramatically expand screening according to Barbara Levy, MD.

Early postpartum blood pressure self-monitoring with physician-guided medication adjustment was linked to sustained reductions in blood pressure among women with hypertensive pregnancies.

Outdated FDA labeling, insurance uncertainty, and lack of clinic workflows are some barriers Jennifer Karlin, MD, PhD, and colleagues found for user-administered injectable contraceptives.

Updated HRSA cervical cancer screening guidelines prioritize hrHPV testing and patient self-collection, a shift that experts say reflects long-standing evidence.

A single subcutaneous dose of RE104 produced rapid and durable improvements in postpartum depression, supporting advancement into phase 3 development.

Provider assumptions about patient capability remain a major barrier to prescribing self-administered DMPA-SC, despite strong patient-reported benefits and supportive national survey data.

A nationwide Norwegian cohort study suggests that prenatal factors, including fetal growth and maternal diabetes, may influence the risk of developing multiple sclerosis in adulthood.

The extended approval and contracpetive efficacy during use from 3 to 5 years was based on a multicenter, single-arm, open-label study (NCT04626596) conducted in the United States.

A large systematic review and meta-analysis found no evidence that paracetamol use during pregnancy increases the risk of autism, ADHD, or intellectual disability in children.

Jennifer Karlin, MD, PhD, explains how COVID-19 increased awareness of self-administered DMPA, but systemic and provider-level barriers still limit access.

A phase 3 trial of oral brexanolone for postpartum depression will continue unchanged following a favorable DSMB safety review.

A population-based study links minimum wage increases to improved maternal cardiovascular health during pregnancy.

Ashley Michnick explained that early findings support RSVpreF pregnancy safety, while emphasizing the need for continued monitoring.

New data suggest that diabetes risk after menopause is driven by cardiometabolic factors rather than when or how menopause occurs.

A large California cohort study shows that aggregating Asian American and Pacific Islander populations can obscure substantial differences in hypertensive disorder risk during pregnancy.

New HRSA guidelines strengthen cervical cancer prevention by adding self-collected hrHPV testing and clarifying no-cost coverage for additional diagnostic services.

Analysis of internal FDA records reveals that mifepristone’s REMS program was shaped by repeated evidence-based safety reviews.

Gestational diabetes rates have increased by 36% in the United States since 2016, with consistent rises across racial and ethnic groups.